Sang Rea Cho

Title: Sang Rea Cho: Innovator in Cancer Prognosis and Diagnosis

Introduction

Sang Rea Cho is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer research, particularly in the areas of genetic markers and therapeutic responsiveness. With a total of 2 patents, his work is paving the way for advancements in cancer diagnosis and treatment.

Latest Patents

Cho's latest patents include a composition for detecting epidermal cell growth factor receptor (EGFR) gene mutations and a genetic marker for early breast cancer prognosis. The first patent focuses on a composition that includes a primer and probe set for detecting EGFR gene mutations. This invention is crucial for predicting and diagnosing a cancer patient's responsiveness to therapeutic agents, as well as for monitoring potential metastasis or relapse. The second patent relates to a genetic marker that aids in predicting or diagnosing the prognosis of early-stage breast cancer. This marker provides essential information for guiding treatment decisions, including the necessity of anticancer therapy.

Career Highlights

Sang Rea Cho is associated with Gencurix Inc., a company dedicated to advancing cancer diagnostics. His innovative work has positioned him as a key figure in the field, contributing to the development of methods that enhance patient care and treatment outcomes.

Collaborations

Cho has collaborated with notable colleagues, including Young Kee Shin and Young-Deug Kim. These partnerships have further enriched his research and development efforts in cancer prognosis and diagnosis.

Conclusion

Sang Rea Cho's contributions to cancer research through his patents and collaborations highlight his commitment to improving patient outcomes. His work continues to influence the future of cancer diagnostics and treatment strategies.